# A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3

Source: https://onco.cc/trials/nct07079631/  
OnCo record `nct07079631` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002, Bevacizumab in colorectal cancer, run by BioNTech SE, now recruiting.

## Summary

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07079631 by BioNTech SE, with 482 participants planned, started 2025-07-18 and due to reach its primary completion in 2030-12. Interventions recorded: BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07079631
- Phase: 1/2
- Setting: A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With Pumitamig and Chemotherapy in Participants With Metastatic Colorectal Cancer
- Sponsor: BioNTech SE
- Enrolled: 482

## Sources

- ClinicalTrials.gov NCT07079631: https://clinicaltrials.gov/study/NCT07079631

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct07079631.json